Live Chat ×
Skip to main content

SUDEP Counseling - Risk Management for Clinicians

webinar graphicJointly presented by the American Epilepsy Society, Epilepsy Foundation SUDEP Institute and Advancing Knowledge in Healthcare, Inc.

Recording date: February 10 and 24, 2014
Expiration date: April 10, 2015
Review date: April 21, 2017

Overview

Studies have shown patients and families overwhelmingly want to know more about Sudden Unexplained Death in Epilepsy (SUDEP). We have heard many health care providers want to have the conversation, but don’t know how. Discussing SUDEP with patients and families requires both knowledge regarding relative risks and comfort with counseling patients and families on a difficult topic. These recordings are designed to provide knowledge and understanding of the risks that patients face and will provide examples of strategies for disclosing the risk for SUDEP. The recordings provide instruction and video examples of counseling patients with differing demographics.

LEARNING OBJECTIVES

  • Counsel patients and families regarding SUDEP as appropriate for the level of risk related to the individual patient's epilepsy, therefore increasing patient and family understanding of the disorder resulting in improved adherence to treatment recommendations.
  • Incorporate established techniques for counseling patients and families in discussions of epilepsy and its potential consequences, providing opportunities for improved communications and patient / family understanding of risks associated with epilepsy.

Program

Part 1: Information About SUDEP and How to Determine Risk
  • Introductions & Overview
  • About SUDEP - Epilepsy-related mortality, definition of SUDEP, epidemiology of SUDEP
  • Risk Factors - Case Control Studies
  • Case Examples
  • Mechanisms of SUDEP
  • Strategies to reduce SUDEP
  • Patient Education - Why talk about SUDEP
  • Moderated Q&A
Part 2: How and When to Discuss SUDEP
  • Why Talk About SUDEP - overview
  • How and When to talk about SUDEP - Case Vignettes 
    • When the patient is at low risk for SUDEP
    • When the patient is at high risk for SUDEP
    • Determining when is the wrong time to discuss SUDEP
    • Impact on Clinical Care and Practice, Discussion Tools
  • Moderated Q&A

TARGET AUDIENCE

This program is appropriate for all who provide care for persons with epilepsy, with all levels of experience (basic, intermediate and advanced). In particular, it is appropriate for physicians including general neurologists, epileptologists, pediatric neurologists and neurosurgeons as well as trainees; for Registered Nurses (RNs), Advance Practice Nurses (APNs, NPs) and Physician Assistants (PAs); and for mental health professionals.

FACULTY, PLANNING COMMITTEE, REVIEWERS’ DISCLOSURES OF FINANCIAL RELATIONSHIPS

In accordance with the ACCME Standards for Commercial Support, the AES requires that any person who is in a position to control content of a CME activity must disclose all relevant financial relationships that they have with a commercial interest. The following individuals contributed to this activity’s content.
Faculty
Jeffrey Buchhalter, M.D., Ph.D., Alberta Children's Hospital, Calgary, Canada
Dr. Buchhalter has the following financial relationships with ACCME-defined Commercial Interest(s): Consultant: Lundbeck Pharmaceuticals, Inc., Eisai, Inc., UpsherSmith

Orrin Devinsky, M.D.
Dr. Devinsky has no financial relationships with ACCME-defined Commercial Interests to disclose that are relevant to this CME activity.

Elson So., M.D., Moderator
Dr. So has no financial relationships with ACCME-defined Commercial Interests to disclose that are relevant to this CME activity.

Planning Committee Members

Jeffrey Buchhalter, M.D., Ph.D., Alberta Children's Hospital, Calgary, Canada
Dr. Buchhalter has the following financial relationships with ACCME-defined Commercial Interest(s): Consultant Lundbeck Pharmaceuticals, Inc., Eisai, Inc., UpsherSmith

The following committee members have no financial relationships with ACCME-defined Commercial Interests to disclose that are relevant to this CME activity.:
Dorothy Caputo, MA, BSN, RN, AKH, Inc.
Orrin Devinsky, M.D.
Elizabeth Donner, M.D.
Patricia O. Shafer, R.N.
Cyndi Wright

CME Reviewer
Kevin Graber, M.D., Stanford University, Stanford, CA
Dr. Graber has no financial relationships with ACCME-defined Commercial Interests to disclose that are relevant to this CME activity.

AES Medical Content Specialist

Paul M. Levisohn, M.D., Children’s Hospital Colorado, Aurora, CO
Dr. Levisohn has no financial relationships with ACCME-defined Commercial Interests to disclose that are relevant to this CME activity.

ACCME-defined Commercial Interest: Any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients.

ACKNOWLEDGEMENT

The live activity was supported by an educational grant from Eisai, Inc. and Lundbeck, Inc.

POLICY ON COMMERCIAL SUPPORT AND CONFLICT OF INTEREST
The American Epilepsy Society maintains a policy on the use of commercial support, which ensures that all educational activities sponsored by the AES provide in-depth presentations that are fair, balanced, independent and scientifically rigorous. All faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to the activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentations. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. This information will also be made available through syllabus materials and faculty presentations.

RESOLUTION OF CONFLICTS OF INTEREST
It is the policy of the American Epilepsy Society to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. In accordance with the ACCME Standards for Commercial Support of CME, the AES implemented the mechanisms of prospective peer review of this CME activity, to identify and resolve any conflicts. Additionally, the content of this activity is based on the best available evidence.

UNAPPROVED USE DISCLOSURE
The American Epilepsy Society requires CME authors to disclose to learners when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Information about pharmaceutical agents/devices that is outside of U.S. Food and Drug Administration approved labeling may be contained in this activity.

DISCLAIMER
This CME activity is for educational purposes only and does not constitute the opinion or endorsement of, or promotion by, the American Epilepsy Society. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label, investigational and/or experimental uses.